Skip to main content
TipRanks
Go Ultimate75% OFF

HABA Laboratories, Inc. (4925) AI Stock Analysis

1 Followers
JP:4925

HABA Laboratories, Inc.

(TSE/TYO:4925)

Select Model
Rating:65.6Neutral
Price Target:JPY 1,780.00â–²(7.88% Upside)
Action:downgraded
Date:11/18/26

The company's financial health is a key strength, driven by a robust balance sheet and a return to profitability. However, the stock is under significant technical pressure, trading in a clear downtrend across all major moving averages with weak momentum. A low P/E ratio and decent dividend yield provide some valuation support, but the negative price trend remains the most significant headwind.

Positive Factors
Strong Gross MarginsConsistently high gross margins indicate that HABA retains meaningful value from its skincare and beauty products after direct costs. This provides a foundation for funding marketing, product development, and distribution while offering some protection if operating expenses rise.
Negative Factors
Limited Revenue GrowthStabilizing revenue is less supportive than a sustained growth trend because it limits the operating leverage available to expand profits. Without stronger demand or broader product adoption, HABA may find it difficult to grow earnings materially beyond the current recovery.

HABA Laboratories, Inc. (4925) vs. iShares MSCI Japan ETF (EWJ)

-5%0%5%10%15%20%25%30%35%JP:4925+0.51%EWJ+15.53%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
JPY 6.25B
Dividend Yield
2.42%
Average Volume (3M)
1,898
Price to Earnings (P/E)
10.8
Beta (1Y)
0.29
Revenue Growth
-2.92%
EPS Growth
-25.96%
Country
Japan
Employees
523
Sector
General
Sector Strength
55
Industry
Household & Personal Products

HABA Laboratories, Inc. Business Overview & Revenue Model

Company Description

Established in Tokyo, Japan, in 1983, HABA Laboratories, Inc. develops and distributes a comprehensive range of skincare, hair, and body care items both domestically and across international markets. Their skincare portfolio encompasses facial cleans...

How the Company Makes Money

HABA Laboratories, Inc. makes money primarily by selling its branded skincare and beauty products to consumers. Key revenue streams typically include (1) direct product sales through company-operated channels (e.g., retail stores and/or e-commerce),...

HABA Laboratories, Inc. Financial Statement Overview

Summary

The company has returned to profitability with a net margin of 6.3% and maintains a very strong balance sheet (debt/equity 0.12, equity ¥9.54B). Cash flow generation is solid, with free cash flow covering 94% of net income, though revenue growth is modest at 1.3%.

Income Statement

75Positive

Balance Sheet

88Very Positive

Cash Flow

70Positive
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue12.04B12.14B12.06B12.32B12.04B12.91B
Gross Profit7.96B7.95B7.99B8.03B8.17B8.79B
EBITDA802.02M898.40M811.56M-1.31B17.05M448.30M
Net Income680.57M760.36M576.57M-2.12B-707.87M-269.03M
Balance Sheet
Total Assets11.66B12.52B12.34B12.43B14.73B15.76B
Cash, Cash Equivalents and Short-Term Investments5.15B5.78B4.74B3.96B4.82B5.65B
Total Debt959.17M1.19B1.82B2.36B2.03B2.56B
Total Liabilities2.31B2.98B3.42B3.92B3.96B4.12B
Stockholders Equity9.35B9.54B8.93B8.51B10.77B11.64B
Cash Flow
Free Cash Flow01.16B1.48B-1.02B-232.69M1.53B
Operating Cash Flow01.24B1.62B-587.92M55.96M1.71B
Investing Cash Flow0484.54M-147.18M-441.79M-214.40M-216.49M
Financing Cash Flow0-780.75M-689.49M171.06M-676.32M-1.51B

HABA Laboratories, Inc. Technical Analysis

Technical Analysis SentimentNegative
Last Price1650.00

Price Trends

50DMA1690.78Negative
100DMA1712.15Negative
200DMA1716.37Negative

Market Momentum

MACD-10.26Positive
RSI34.15Neutral
STOCH31.69Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4925, the sentiment is Negative. The current price of 1650.00 is below the 20-day moving average (MA) of 1665.75, below the 50-day MA of 1690.78, and below the 200-day MA of 1716.37, indicating a bearish trend. The MACD of -10.26 indicates Positive momentum. The RSI at 34.15 is Neutral, neither overbought nor oversold. The STOCH value of 31.69 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4925.

HABA Laboratories, Inc. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

JP:4925 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
JP:4933JP:493383OutperformJPY 44.30B22.82―0.88%19.48%-22.87%
JP:4918JP:491869NeutralJPY 2.91B15.00―2.92%-5.54%-55.93%
JP:4926JP:492668NeutralJPY 5.33B20.94―1.61%1.51%-18.54%
JP:4925JP:492566NeutralJPY 6.24B10.81―2.42%-2.92%-25.96%
JP:4920JP:492058NeutralJPY 2.21B8.25―2.84%9.96%2053.18%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
JP:4936JP:493644NeutralJPY 6.65B-13.57―3.62%-0.08%-246.12%

* General Sector Average

Performance Comparison

-25%0%25%50%75%JP:4925JP:4918JP:4920JP:4926JP:4933JP:4936Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
JP:4925 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
JP:4925HABA Laboratories, Inc.1650.0016.130.99%
JP:4918Ivy Cosmetics Corporation513.00196.1161.88%
JP:4920Nippon Shikizai, Inc.1056.007.470.71%
JP:4926C'BON COSMETICS Co., Ltd.1246.0071.306.07%
JP:4933I-ne CO., LTD.2501.001115.2280.48%
JP:4936AXXZIA, Inc.276.00-123.10-30.84%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 17, 2026